Mayne Pharma Group

Mayne Pharma Group Conversion FCF

Taux de Conversion FCL (FCL/EBITDA) de Mayne Pharma Group (MYX.AX) au 18 oct. 2026 est 51,79 %. L'année précédente, Taux de Conversion FCL (FCL/EBITDA) était -5,53 % — une variation de -1 035,79 % (plus élevé).

Conversion FCF

51,79 %

YoY

-1 035,79%

Dernière mise à jour:

Taux de Conversion FCL (FCL/EBITDA) de Mayne Pharma Group est 2026 51,79 % . Taux de Conversion FCL (FCL/EBITDA) de Mayne Pharma Group était 2025 -5,53 % . Elle diminue ainsi de -1 035,79% plus élevé par rapport à l'année précédente.

L'histoire de Mayne Pharma Group Conversion FCF

  • 3 ans

  • 10 ans

  • 25 ans

  • Max

Conversion FCF
Date
Conversion FCF
1 janv. 2019
-33,92 AUD
1 janv. 2020
-56,75 AUD
1 janv. 2021
-10,63 AUD
1 janv. 2022
6,78 AUD
1 janv. 2023
-223,71 AUD
1 janv. 2024
20,75 AUD
1 janv. 2025
-5,53 AUD
1 janv. 2026
51,79 AUD
L'histoire de Mayne Pharma Group Conversion FCF
ANNÉEConversion FCFYoY
51,79 %-1 035,79%
-5,53 %-126,66%
20,75 %-109,28%
-223,71 %-3 401,66%
6,78 %-163,73%
-10,63 %-81,27%
-56,75 %+67,33%
-33,92 %-32,50%
-50,24 %-62,81%
-135,10 %-311,03%
64,02 %-72,78%
235,16 %+128,27%
103,02 %—

Accéder à ces données via l’API Eulerpool

100 000 requêtes/mois gratuites · sans carte bancaire

Mayne Pharma Group Analyse d'actions

Que fait Mayne Pharma Group ? Mayne Pharma was founded in 1845 as a herbal medicine manufacturer and has since evolved into a leading pharmaceutical development and production company with facilities in Australia and the USA. The company's headquarters are located in Sydney, Australia, and it employs over 1,100 people worldwide. The company's history saw it transition from herbal medicine to the pharmaceutical industry, leading to its renaming as Mayne Nickless Ltd in 1981. In the year 2000, Mayne Pharma was established as a subsidiary specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma expanded its product range and eventually entered the US market in 2007. Mayne Pharma's business model focuses on the production and distribution of generic and specialty pharmaceuticals through various global distribution channels. The company is committed to research and development to develop new and improve existing products, aiming to expand its offering and increase market presence. This has allowed Mayne Pharma to establish a strong position in the pharmaceutical industry through portfolio expansion and entry into new markets. The company has three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the US, Australia, Canada, and other countries. Mayne Pharma is able to cost-effectively produce medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on drugs for the treatment of diseases such as cancer, pain, and cardiovascular disorders. Mayne Pharma strives to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold globally, including creams, lip care products, and sunscreens. This division is steadily growing and has significant potential as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma offers a wide range of products, from medications for everyday ailments to life-saving specialty preparations. Key products include Doryx, an oral antibiotic therapy for mild to moderate acne; Lonsurf, a cancer-fighting drug that extends survival in advanced colorectal cancer patients; Kapanol, a long-acting opioid for pain relief in patients with severe pain; Tolsura, an easy-to-use medication for the treatment of fungal infections, particularly suited for patients who have difficulty swallowing tablets; Zenavod, a topical medication for the treatment of vaginal infections; and Golden Glow sunscreen, a high-quality SPF 50+ sunscreen that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company focused on the development and production of generic and specialty pharmaceuticals. With its extensive product range and presence in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group est l'une des entreprises les plus populaires sur Eulerpool.

Questions fréquemment posées sur l'action Mayne Pharma Group

Taux de Conversion FCL (FCL/EBITDA) de Mayne Pharma Group s'élève à 51,79 % en 2026.

Taux de Conversion FCL (FCL/EBITDA) de Mayne Pharma Group a changé de -5,53 % à 51,79 %, ce qui représente une variation de -1 035,79 %. La valeur est plus élevé qu'l'année précédente.

Sur Eulerpool, vous trouverez l'évolution historique complète de Mayne Pharma Group de Taux de Conversion FCL (FCL/EBITDA) depuis 2006 – avec des valeurs annuelles, des graphiques et une analyse détaillée.

La conversion FCL mesure l'efficacité avec laquelle l'EBITDA se convertit en flux de trésorerie libre. Une conversion plus élevée indique une allocation de capital efficace et des coûts de maintenance faibles.

Un 'bon' varie selon le secteur et le stade de l'entreprise. Sur Eulerpool, vous pouvez comparer Mayne Pharma Group de Taux de Conversion FCL (FCL/EBITDA) avec les pairs du secteur et la moyenne du secteur pour évaluer son attrait.

Pour évaluer de Taux de Conversion FCL (FCL/EBITDA), il est essentiel de le comparer avec les pairs du même secteur. Sur Eulerpool, vous pouvez trouver des comparaisons directes du secteur pour Taux de Conversion FCL (FCL/EBITDA).

Accéder à ces données via l’API Eulerpool

100 000 requêtes/mois gratuites · sans carte bancaire

Flux de trésorerie — Mayne Pharma Group

Toutes les Métriques Clés — Mayne Pharma Group

Croissance